Certara, Inc. $CERT Stake Lifted by Mendel Money Management

Mendel Money Management increased its stake in shares of Certara, Inc. (NASDAQ:CERT) by 24.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,305 shares of the company’s stock after buying an additional 26,740 shares during the quarter. Mendel Money Management’s holdings in Certara were worth $1,571,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. AdvisorNet Financial Inc bought a new position in Certara during the 2nd quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new position in Certara during the 1st quarter worth $31,000. AlphaQuest LLC bought a new position in Certara during the 1st quarter worth $39,000. Quarry LP bought a new position in Certara during the 1st quarter worth $98,000. Finally, Associated Banc Corp bought a new position in shares of Certara in the first quarter worth $101,000. 73.96% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the transaction, the insider owned 73,979 shares of the company’s stock, valued at $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. Zacks Research upgraded shares of Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Morgan Stanley assumed coverage on shares of Certara in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price for the company. Barclays increased their target price on shares of Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, UBS Group decreased their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Certara presently has an average rating of “Hold” and a consensus price target of $15.63.

Certara Trading Down 3.0%

Shares of CERT stock opened at $12.13 on Wednesday. The stock has a 50-day simple moving average of $11.73 and a 200 day simple moving average of $11.65. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $15.69. The stock has a market capitalization of $1.95 billion, a P/E ratio of 242.65 and a beta of 1.45. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.57 million for the quarter, compared to the consensus estimate of $104.14 million. During the same period in the prior year, the business earned $0.07 EPS. The company’s quarterly revenue was up 12.1% compared to the same quarter last year. On average, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.